Contrafect Corporation (NASDAQ: CFRX) is one of those ideas that we'd all love to be true. That there is, or at least could be, some new and non-antibiotic method of dealing with antibiotic resistant infections. Actually finding one of those that truly works would of course be hugely valuable. More valuable than a new antibiotic even as there would be no limitations upon widespread use - the problem with a new antibiotic being that we don't want to use it because that will cause resistant strains. So the idea is good, even great. But there's also that little matter of performance that has to be dealt with.
There CFRX isn't doing so well. Back in July last year the Contrafect trial was stopped by the Data Board (DSMB) on the basis that the results being shown were below the “futility” level. The stock dropped 76% overnight and has continued down since, we're actually at a 99.3% loss over 12 months. We can pretty much call that a total wipeout. Testing continues but we're still at Phase I/II trials, which is early days in the process. That's also a very expensive part of the process and there's absolutely nothing as yet that can produce any revenue. The company is, as with all such pharma companies, entirely dependent upon regular infusions of shareholder capital to keep going.

Contrafect share price from NASDAQ
Finances are in fact worse than we might think. In the last results we seem to have cash (and equivalents) at slightly less than current liabilities. We've losses in the mid $60 million range, there's no obvious source of more cash to be able to fund such ongoing expenses. Well, except a call upon the shareholders that is.
But Contrafect has a market capitalisation of $1.4 million or so. Yes, a market value of one and a half million but they need $60 million and more a year to keep going. That's not going to get raised without some substantial dilution.
The net of all of this is that Contrafect needs some Hail Mary pass in order to keep going, let alone to thrive. As we've no news of such a thing coming to pass we‘ll have to assume that it's not imminent despite the stock price jump. We end up ascribing this price move to low levels of trade in an extremely thin market. As such we'd expect - absent any other news - it to fade away again. As it already is doing intraday.



